mitoxantrone has been researched along with Primary Peritonitis in 4 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitoxantrone is an effective drug against ovarian cancer cells in vitro and is an attractive agent for IP therapy because of its very low peritoneal clearance." | 6.67 | Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. ( Audhuy, B; Barats, JC; Bergerat, JP; Dellenbach, P; Duclos, B; Dufour, P; Giron, C; Oberling, F; Renaud, R; Ritter, J, 1994) |
| "Mitoxantrone has demonstrable clinical activity when administered intravenously in a wide range of malignancies." | 2.67 | Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer. ( Aartsen, E; Dubbelman, R; Mandjes, I; McVie, JG; Oza, AM; Soepenberg, O; ten Bokkel Huinink, W, 1994) |
| "Mitoxantrone is an effective drug against ovarian cancer cells in vitro and is an attractive agent for IP therapy because of its very low peritoneal clearance." | 2.67 | Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. ( Audhuy, B; Barats, JC; Bergerat, JP; Dellenbach, P; Duclos, B; Dufour, P; Giron, C; Oberling, F; Renaud, R; Ritter, J, 1994) |
| "Mitoxantrone (MXN) has demonstrated therapeutic efficacy in the intraperitoneal treatment of malignancies." | 1.30 | Toxicity of a particulate formulation for the intraperitoneal application of mitoxantrone. ( Eichler, HG; Luftensteiner, CP; Paul, B; Schwendenwein, I; Viernstein, H; Wölfl, G, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oza, AM | 1 |
| ten Bokkel Huinink, W | 1 |
| Dubbelman, R | 1 |
| Soepenberg, O | 1 |
| Mandjes, I | 1 |
| Aartsen, E | 1 |
| McVie, JG | 1 |
| Dufour, P | 1 |
| Bergerat, JP | 1 |
| Barats, JC | 1 |
| Giron, C | 1 |
| Duclos, B | 1 |
| Dellenbach, P | 1 |
| Ritter, J | 1 |
| Renaud, R | 1 |
| Audhuy, B | 1 |
| Oberling, F | 1 |
| Tarraza, HM | 1 |
| Boyce, CR | 1 |
| Smith, WG | 1 |
| Jones, MA | 1 |
| Luftensteiner, CP | 1 |
| Schwendenwein, I | 1 |
| Eichler, HG | 1 |
| Paul, B | 1 |
| Wölfl, G | 1 |
| Viernstein, H | 1 |
2 trials available for mitoxantrone and Primary Peritonitis
| Article | Year |
|---|---|
Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer.
Topics: Abdominal Pain; Female; Hematologic Diseases; Humans; Injections, Intraperitoneal; Middle Aged; Mito | 1994 |
Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1994 |
2 other studies available for mitoxantrone and Primary Peritonitis
| Article | Year |
|---|---|
Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy.
Topics: Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Humans; Infusions, Parenter | 1993 |
Toxicity of a particulate formulation for the intraperitoneal application of mitoxantrone.
Topics: Animals; Antineoplastic Agents; Blood Cell Count; Body Weight; Eating; Female; Humans; Injections, I | 1999 |